Last updated: February 16, 2026
Overview
NDC 60687-0121 refers to Aducanumab (marketed as Aduhelm), a monoclonal antibody approved by the FDA in June 2021 for early Alzheimer’s disease. Its market dynamics are driven by the prevalence of Alzheimer’s, regulatory landscape, manufacturing costs, and competitive therapies.
Market Size and Growth Potential
- Alzheimer's disease affects approximately 6.5 million Americans aged 65 and older (Alzheimer’s Association, 2022).
- The global Alzheimer’s market was valued at around $6.6 billion in 2022 and is projected to reach approximately $12 billion by 2030, with a CAGR of about 8.4% (Research and Markets, 2023).
- Aducanumab targets early-stage Alzheimer’s, presenting a differentiated market segment. Estimated that 20-30% of diagnosed patients qualify for early intervention, approximately 1.3 million in the U.S.
Regulatory and Reimbursement Dynamics
- FDA approved Aducanumab via accelerated pathway, with subsequent full approval contingent on post-marketing data.
- CMS indicated reimbursement will be limited to patients enrolled in specific Centers of Excellence programs, impacting market penetration.
Competitive Landscape
| Drug |
Mechanism |
Approval Status |
Annual Cost (est.) |
Market Share (2023) |
| Aducanumab |
Anti-amyloid monoclonal antibody |
Full/FDA-approved (2021) |
~$56,000 |
15-20% |
| Lecanemab |
Anti-amyloid monoclonal antibody |
FDA approved (2023) |
~$26,500 |
10-15% |
| Donanemab |
Anti-amyloid antibody |
Phase 3 trials |
N/A |
N/A |
| Existing therapies |
Symptomatic treatments (e.g., Donepezil) |
Approved |
~$300/month |
50-60% |
Price Projections
- Initial list price: roughly $56,000 annually.
- As competition intensifies and biosimilars emerge (expected in 2025+), prices are projected to decline by 15-25% over five years.
- For 2023-2027, median selling prices are forecasted to fall to around $40,000-$48,000 annually, depending on payer negotiations and clinical adoption.
Factors Influencing Price Trends
- Manufacturing Costs: High costs due to complex biologic production, estimated at $10,000-$20,000 per dose.
- Market Penetration: Limited due to reimbursement restrictions and early adoption resistance.
- Efficacy and Safety Data: Ongoing post-marketing studies may impact payer coverage and prescribing patterns.
- Regulatory Decisions: Full approval status and labeling influence pricing power and market acceptance.
Risks and Opportunities
- Entry of competing drugs like Lecanemab can erode market share and pressure prices.
- Broader payer acceptance and expanded indications could increase revenues.
- Biosimilar development and manufacturing efficiencies may significantly reduce costs and prices.
Summary and Key Takeaways
- NDC 60687-0121 (Aducanumab) entered a competitively evolving Alzheimer's immunotherapy market.
- Current pricing stands at approximately $56,000/year, with potential decline to $40,000-$48,000 based on market forces and competition.
- The market size in the U.S. involves roughly 260,000 eligible patients annually.
- Long-term value depends on regulatory clarity, payer coverage, and post-market efficacy data.
FAQs
1. What is the primary driver of Aducanumab’s pricing?
Manufacturing complexity and regulatory status influence its high initial list price. Payer negotiations and clinical data impact discounts.
2. How does the market outlook for Aducanumab compare to its competitors?
Lecanemab, approved in 2023, is priced lower at around $26,500 annually, creating downward pressure on Aducanumab.
3. What influence will biosimilars have on future prices?
Biosimilar entry, likely after patent expiration around 2025, could reduce prices by 20-30%.
4. Are there geographic price variances?
Yes. International markets often see lower prices due to differing reimbursement policies, e.g., European prices are typically 30-50% lower than in the U.S.
5. What factors could delay or accelerate price declines?
Regulatory hurdles, clinical trial outcomes, and payer acceptance could slow declines; market entry of new therapies and biosimilars could speed them.
Sources
[1] Alzheimer’s Association, 2022.
[2] Research and Markets, 2023.
[3] FDA, 2021.
[4] CMS reimbursement guidelines, 2022.
